scholarly journals Clinicopathologic and molecular characteristics of gastric cancer showing gastric and intestinal mucin phenotype

2015 ◽  
Vol 106 (8) ◽  
pp. 951-958 ◽  
Author(s):  
Naohide Oue ◽  
Kazuhiro Sentani ◽  
Naoya Sakamoto ◽  
Wataru Yasui
Pathobiology ◽  
2016 ◽  
Vol 84 (1) ◽  
pp. 16-24 ◽  
Author(s):  
Takeharu Imai ◽  
Naohide Oue ◽  
Masahiro Nishioka ◽  
Shoichiro Mukai ◽  
Takashi Oshima ◽  
...  

2013 ◽  
Vol 137 (8) ◽  
pp. 1047-1053 ◽  
Author(s):  
Dae Hwan Kim ◽  
Nari Shin ◽  
Gwang Ha Kim ◽  
Geum Am Song ◽  
Tae-Yong Jeon ◽  
...  

Context.—The clinical validity of mucin expression in gastric cancer is debated. Whereas several reports demonstrate a correlation between mucin expression and prognosis, others deny such an association. Objectives.—This survival analysis study aims to elucidate the prognostic significance of mucin expression in gastric cancer. Design.—A retrospective survival analysis was done with 412 cases of gastric cancer characterized on the basis of MUC immunohistochemistry using MUC2, MUC5AC, MUC6, and CD10 antibodies; the cases were divided into those with a gastric, an intestinal, or a null mucin phenotype based on the predominant mucin. Results.—There was no association between mucin expression and survival when considering overall gastric cancers or the advanced gastric cancer subtype. However, early gastric cancers with a gastric mucin phenotype showed longer survival than those with an intestinal mucin phenotype (P = .01) or a null phenotype (P = .01). In particular, MUC5AC-positive early gastric cancers resulted in longer survival than did those that did not express MUC5AC (P = .009). The loss of MUC5AC expression was identified as an independent, poor prognostic factor in early gastric cancers using the Cox regression proportional hazard model (hazard ratio, 3.50; P = .045). Conclusions.—MUC5AC expression is significantly associated with patient survival and can be used to predict outcomes in the gastric cancers, especially in the early gastric cancers.


2012 ◽  
Vol 33 (5) ◽  
pp. 1081-1088 ◽  
Author(s):  
K. Sentani ◽  
N. Oue ◽  
Y. Naito ◽  
N. Sakamoto ◽  
K. Anami ◽  
...  

2020 ◽  
Vol 10 ◽  
Author(s):  
Astrid E. Slagter ◽  
Marieke A. Vollebergh ◽  
Edwin P. M. Jansen ◽  
Johanna W. van Sandick ◽  
Annemieke Cats ◽  
...  

Gastric cancer is the fifth most common cancer worldwide and has a high mortality rate. In the last decades, treatment strategy has shifted from an exclusive surgical approach to a multidisciplinary strategy. Treatment options for patients with resectable gastric cancer as recommended by different worldwide guidelines, include perioperative chemotherapy, pre- or postoperative chemoradiotherapy and postoperative chemotherapy. Although gastric cancer is a heterogeneous disease with respect to patient-, tumor-, and molecular characteristics, the current standard of care is still according to a one-size-fits-all approach. In this review, we discuss the background of the different treatment strategies in resectable gastric cancer including the current standard, the specific role of radiotherapy, and describe the current areas of research and potential strategies for personalization of therapy.


2013 ◽  
Author(s):  
Rebekka Krumbach ◽  
Seong-Ho Kong ◽  
Woo Ho Kim ◽  
Julia Schüler ◽  
Andreas Ackermann ◽  
...  

2019 ◽  
Vol Volume 11 ◽  
pp. 5047-5054
Author(s):  
Elisabetta Cavalcanti ◽  
Francesco De Michele ◽  
Giulio Lantone ◽  
A. Panarese ◽  
Maria Lucia Caruso

Theranostics ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 5489-5500
Author(s):  
Anqiang Wang ◽  
Zhongwu Li ◽  
Meng Wang ◽  
Shuqin Jia ◽  
Jiahu Chen ◽  
...  

2011 ◽  
Vol 46 (9) ◽  
pp. 1064-1070 ◽  
Author(s):  
Masaaki Kobayashi ◽  
Manabu Takeuchi ◽  
Yoichi Ajioka ◽  
Satoru Hashimoto ◽  
Akito Sato ◽  
...  

2006 ◽  
Vol 56 (4) ◽  
pp. 200-205 ◽  
Author(s):  
Junichi Motoshita ◽  
Hirofumi Nakayama ◽  
Kiyomi Taniyama ◽  
Keisuke Matsusaki ◽  
Wataru Yasui

Sign in / Sign up

Export Citation Format

Share Document